These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11159177)

  • 1. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
    Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
    Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor.
    Schlomm T; Gunawan B; Schulten HJ; Sander B; Thangavelu K; Graf N; Leuschner I; Ringert RH; Füzesi L
    Clin Cancer Res; 2005 Jun; 11(12):4382-7. PubMed ID: 15958621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
    Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
    Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
    Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
    Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.
    Williams RD; Hing SN; Greer BT; Whiteford CC; Wei JS; Natrajan R; Kelsey A; Rogers S; Campbell C; Pritchard-Jones K; Khan J
    Genes Chromosomes Cancer; 2004 Sep; 41(1):65-79. PubMed ID: 15236318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased microvascular density predicts relapse in Wilms' tumor.
    Abramson LP; Grundy PE; Rademaker AW; Helenowski I; Cornwell M; Katzenstein HM; Reynolds M; Arensman RM; Crawford SE
    J Pediatr Surg; 2003 Mar; 38(3):325-30; discussion 325-30. PubMed ID: 12632343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.
    Benetkiewicz M; Díaz de Ståhl T; Gördör A; Pfeifer S; Wittmann S; Gessler M; Dumanski JP
    Int J Cancer; 2006 Aug; 119(3):571-8. PubMed ID: 16496407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic hybridization and its application to Wilms' tumorigenesis.
    Getman ME; Houseal TW; Miller GA; Grundy PE; Cowell JK; Landes GM
    Cytogenet Cell Genet; 1998; 82(3-4):284-90. PubMed ID: 9858837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
    Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
    Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
    Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
    Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence.
    Lu YJ; Birdsall S; Osin P; Gusterson B; Shipley J
    Genes Chromosomes Cancer; 1997 Nov; 20(3):275-81. PubMed ID: 9365835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
    Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
    J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.